Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07848243). This is a study registration, not published results. Lead sponsor: Peking University Cancer Hospital & Institute. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 50 participants (ESTIMATED). Conditions: Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers. Interventions: DRUG: 18F-FDG; DRUG: [18F]F-PDL1-3. Primary outcome measures: Safety - Tracer-related Adverse Events , From the start of radiotracer administration through 7 days after injection.; Feasibility of PET/CT Imaging , Dynamic PET/CT scanning from 0 to 40 minutes post-injection; static PET/CT scans at 1 hour, 2 hours, and 3 hours post-injection.; Radiochemical Purity , 1 h before each injection on each imaging day; Bacterial Endotoxins , Before preparation of each drug batch.Once a month.. Brief summary: \[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors